

# Thomas Helland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6550148/publications.pdf>

Version: 2024-02-01

14  
papers

153  
citations

1684188

5  
h-index

1199594

12  
g-index

14  
all docs

14  
docs citations

14  
times ranked

312  
citing authors

#	ARTICLE	IF	CITATIONS
1	Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1368-1374.	3.6	3
2	Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study. <i>BMJ Open</i> , 2022, 12, e054404.	1.9	4
3	Low 4-OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen. <i>Molecular Oncology</i> , 2021, 15, 957-967.	4.6	10
4	Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 201.	2.5	13
5	Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. <i>Npj Breast Cancer</i> , 2021, 7, 34.	5.2	5
6	Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites. <i>Journal of Personalized Medicine</i> , 2021, 11, 507.	2.5	4
7	First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study. <i>ESMO Open</i> , 2020, 5, e000859.	4.5	6
8	Relationship between CYP2D6 genotype, tamoxifen metabolites, and adverse events, tumor biomarkers and breast cancer recurrence in a low-dose phase III trial in noninvasive disease.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1553-1553.	1.6	0
9	A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 185, 57-70.	2.5	5
10	Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 185-195.	2.5	17
11	Angiotensin-like protein 8/betatrophin as a new determinant of type 2 diabetes remission after bariatric surgery. <i>Translational Research</i> , 2017, 184, 35-44.e4.	5.0	22
12	Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. <i>Breast Cancer Research</i> , 2017, 19, 125.	5.0	58
13	The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0122339.	2.5	3
14	Cyclin C interacts with steroid receptor coactivator 2 and upregulates cell cycle genes in MCF-7 cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 2383-2391.	4.1	3